TrialClinical lung cancer2017

Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.

Angel Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.